{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:26:13Z","timestamp":1760747173090,"version":"build-2065373602"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CMU Junior Research Fellowship Program, Chiang Mai University","award":["2564"],"award-info":[{"award-number":["2564"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-20324-y","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:50:06Z","timestamp":1760712606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impaired antibody responses to heterologous ChAdOx1 nCoV-19 and BNT162b2 vaccination in individuals with type 2 diabetes"],"prefix":"10.1038","volume":"15","author":[{"given":"Wipawee","family":"Saenwongsa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudarat","family":"Kingpha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phonnipha","family":"Saythanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sopita","family":"Sopila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganjana","family":"Lertmemongkolchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chidchamai","family":"Kewcharoenwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"20324_CR1","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/d41586-020-00758-2","volume":"579","author":"E Callaway","year":"2020","unstructured":"Callaway, E., Cyranoski, D., Mallapaty, S., Stoye, E. & Tollefson, J. The coronavirus pandemic in five powerful charts. Nature 579, 482\u2013483. https:\/\/doi.org\/10.1038\/d41586-020-00758-2 (2020).","journal-title":"Nature"},{"key":"20324_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.23750\/abm.v91i1.9397","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta, D., &  Vanelli, M. WHO Declares: COVID-19 a pandemic. Acta Biomed. 91, 157\u2013160. https:\/\/doi.org\/10.23750\/abm.v91i1.9397 (2020).","journal-title":"Acta Biomed."},{"key":"20324_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-021-00481-y","volume":"6","author":"P Jin","year":"2021","unstructured":"Jin, P., Li, J., Pan, H., Wu, Y. & Zhu, F. Immunological surrogate endpoints of COVID-2019 vaccines: The evidence we have versus the evidence we need. Signal. Transduct. Target. Ther. 6, 48. https:\/\/doi.org\/10.1038\/s41392-021-00481-y (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"20324_CR4","doi-asserted-by":"publisher","unstructured":"Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin. Microbiol. 58 https:\/\/doi.org\/10.1128\/JCM.02107-20 (2020).","DOI":"10.1128\/JCM.02107-20"},{"key":"20324_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","volume":"21","author":"D Cromer","year":"2021","unstructured":"Cromer, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21, 395\u2013404. https:\/\/doi.org\/10.1038\/s41577-021-00550-x (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"20324_CR6","doi-asserted-by":"publisher","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity 52, 971\u2013977 e973, (2020). https:\/\/doi.org\/10.1016\/j.immuni.2020.04.023","DOI":"10.1016\/j.immuni.2020.04.023"},{"key":"20324_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211. https:\/\/doi.org\/10.1038\/s41591-021-01377-8 (2021).","journal-title":"Nat. Med."},{"key":"20324_CR8","unstructured":"Organisation, W. H. (World Health Organisation, (2023). https:\/\/www.who.int\/who-documents-detail\/draft-lanscape-of-covid-19-candidate-vaccines."},{"key":"20324_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","volume":"21","author":"M Sadarangani","year":"2021","unstructured":"Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21, 475\u2013484. https:\/\/doi.org\/10.1038\/s41577-021-00578-z (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"20324_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626\u2013636. https:\/\/doi.org\/10.1038\/s41577-021-00592-1 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"20324_CR11","doi-asserted-by":"publisher","unstructured":"Nangsue, C., Srisurapanont, K. & Sudjaritruk, T. A. Comparison of the immunogenicity and safety of an additional heterologous versus homologous COVID-19 vaccination among Non-Seroconverted immunocompromised patients after a Two-Dose primary series of mRNA vaccination: A systematic review and Meta-Analysis. Vaccines (Basel). 12 https:\/\/doi.org\/10.3390\/vaccines12050468 (2024).","DOI":"10.3390\/vaccines12050468"},{"key":"20324_CR12","doi-asserted-by":"publisher","first-page":"e48255","DOI":"10.2196\/48255","volume":"10","author":"P Kumwichar","year":"2024","unstructured":"Kumwichar, P. et al. Durability of the effectiveness of heterologous COVID-19 vaccine regimens in thailand: retrospective cohort study using National registration data. JMIR Public. Health Surveill. 10, e48255. https:\/\/doi.org\/10.2196\/48255 (2024).","journal-title":"JMIR Public. Health Surveill"},{"key":"20324_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.jiph.2023.07.017","volume":"16","author":"J Yoo","year":"2023","unstructured":"Yoo, J. et al. Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the Omicron variant than homologous vaccination. J. Infect. Public. Health. 16, 1537\u20131543. https:\/\/doi.org\/10.1016\/j.jiph.2023.07.017 (2023).","journal-title":"J. Infect. Public. Health"},{"key":"20324_CR14","doi-asserted-by":"publisher","first-page":"817597","DOI":"10.3389\/fimmu.2022.817597","volume":"13","author":"E Farid","year":"2022","unstructured":"Farid, E., Herrera-Uribe, J. & Stevenson, N. J. The effect of age, gender and comorbidities upon SARS-CoV-2 Spike antibody induction after two doses of sinopharm vaccine and the effect of a pfizer\/biontech booster vaccine. Front. Immunol. 13, 817597. https:\/\/doi.org\/10.3389\/fimmu.2022.817597 (2022).","journal-title":"Front. Immunol."},{"key":"20324_CR15","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3389\/fimmu.2018.02109","volume":"9","author":"C Kewcharoenwong","year":"2018","unstructured":"Kewcharoenwong, C., Prabowo, S. A., Bancroft, G. J., Fletcher, H. A. & Lertmemongkolchai, G. Glibenclamide reduces primary human monocyte functions against tuberculosis infection by enhancing M2 polarization. Front. Immunol. 9, 2109. https:\/\/doi.org\/10.3389\/fimmu.2018.02109 (2018).","journal-title":"Front. Immunol."},{"key":"20324_CR16","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41598-020-60213-0","volume":"10","author":"W Saenwongsa","year":"2020","unstructured":"Saenwongsa, W. et al. Metformin-induced suppression of IFN-alpha via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes. Sci. Rep. 10, 3229. https:\/\/doi.org\/10.1038\/s41598-020-60213-0 (2020).","journal-title":"Sci. Rep."},{"key":"20324_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/1573399815666191024085838","volume":"16","author":"A Berbudi","year":"2020","unstructured":"Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr. Diabetes Rev. 16, 442\u2013449. https:\/\/doi.org\/10.2174\/1573399815666191024085838 (2020).","journal-title":"Curr. Diabetes Rev."},{"key":"20324_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/trstmh\/try124","volume":"113","author":"S Dunachie","year":"2019","unstructured":"Dunachie, S. & Chamnan, P. The double burden of diabetes and global infection in low and middle-income countries. Trans. R Soc. Trop. Med. Hyg. 113, 56\u201364. https:\/\/doi.org\/10.1093\/trstmh\/try124 (2019).","journal-title":"Trans. R Soc. Trop. Med. Hyg."},{"key":"20324_CR19","doi-asserted-by":"publisher","first-page":"798117","DOI":"10.3389\/fimmu.2021.798117","volume":"12","author":"S Jochum","year":"2021","unstructured":"Jochum, S. et al. Clinical utility of Elecsys anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial. Front. Immunol. 12, 798117. https:\/\/doi.org\/10.3389\/fimmu.2021.798117 (2021).","journal-title":"Front. Immunol."},{"key":"20324_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650\u2013655. https:\/\/doi.org\/10.1126\/science.abc6952 (2020).","journal-title":"Science"},{"key":"20324_CR21","doi-asserted-by":"publisher","unstructured":"Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 545. https:\/\/doi.org\/10.1016\/j.it.2020.04.008 (2020).","DOI":"10.1016\/j.it.2020.04.008"},{"key":"20324_CR22","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein. Cell 183, 1735. https:\/\/doi.org\/10.1016\/j.cell.2020.11.032 (2020).","journal-title":"Cell"},{"key":"20324_CR23","doi-asserted-by":"publisher","unstructured":"El-Ghitany, E. M., Hashish, M. H., Farghaly, A. G. & Omran, E. A. Determining the SARS-CoV-2 anti-spike cutoff level denoting neutralizing activity using two commercial kits. Vaccines (Basel). 10. https:\/\/doi.org\/10.3390\/vaccines10111952 (2022).","DOI":"10.3390\/vaccines10111952"},{"key":"20324_CR24","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/s41598-022-07597-3","volume":"12","author":"N Hofmann","year":"2022","unstructured":"Hofmann, N., Grossegesse, M., Neumann, M., Schaade, L. & Nitsche, A. Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2. Sci. Rep. 12, 3549. https:\/\/doi.org\/10.1038\/s41598-022-07597-3 (2022).","journal-title":"Sci. Rep."},{"key":"20324_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.31083\/j.fbl2702074","volume":"27","author":"M Pieri","year":"2022","unstructured":"Pieri, M. et al. Performance evaluation of four surrogate virus neutralization tests (sVNTs) in comparison to the in vivo gold standard test. Front. Biosci. (Landmark Ed). 27, 74. https:\/\/doi.org\/10.31083\/j.fbl2702074 (2022).","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"20324_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA 324, 951\u2013960. https:\/\/doi.org\/10.1001\/jama.2020.15543 (2020).","journal-title":"JAMA"},{"key":"20324_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 181\u2013192. https:\/\/doi.org\/10.1016\/S1473-3099(20)30843-4 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"20324_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.cmi.2021.10.006","volume":"28","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clin. Microbiol. Infect. 28, 410\u2013418. https:\/\/doi.org\/10.1016\/j.cmi.2021.10.006 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"20324_CR29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat. Med. 27, 1525\u20131529. https:\/\/doi.org\/10.1038\/s41591-021-01449-9 (2021).","journal-title":"Nat. Med."},{"key":"20324_CR30","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N Engl. J. Med. 385, e84. https:\/\/doi.org\/10.1056\/NEJMoa2114583 (2021).","journal-title":"N Engl. J. Med."},{"key":"20324_CR31","doi-asserted-by":"publisher","unstructured":"Xiang, F. et al. H. Impaired antibody responses were observed in patients with type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines. Virol J. 20(1), 22. https:\/\/doi.org\/10.1186\/s12985-023-01983-7 (2023).","DOI":"10.1186\/s12985-023-01983-7"},{"key":"20324_CR32","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","volume":"386","author":"RL Atmar","year":"2022","unstructured":"Atmar, R. L. et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl. J. Med. 386, 1046\u20131057. https:\/\/doi.org\/10.1056\/NEJMoa2116414 (2022).","journal-title":"N Engl. J. Med."},{"key":"20324_CR33","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41467-021-21111-9","volume":"12","author":"S Marot","year":"2021","unstructured":"Marot, S. et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat. Commun. 12, 844. https:\/\/doi.org\/10.1038\/s41467-021-21111-9 (2021).","journal-title":"Nat. Commun."},{"key":"20324_CR34","doi-asserted-by":"publisher","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457\u2013466 e454, (2022). https:\/\/doi.org\/10.1016\/j.cell.2021.12.033","DOI":"10.1016\/j.cell.2021.12.033"},{"key":"20324_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","volume":"444","author":"GS Hotamisligil","year":"2006","unstructured":"Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860\u2013867. https:\/\/doi.org\/10.1038\/nature05485 (2006).","journal-title":"Nature"},{"key":"20324_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd4275","volume":"13","author":"MY Donath","year":"2014","unstructured":"Donath, M. Y. Targeting inflammation in the treatment of type 2 diabetes: Time to start. Nat. Rev. Drug Discov. 13, 465\u2013476. https:\/\/doi.org\/10.1038\/nrd4275 (2014).","journal-title":"Nat. Rev. Drug Discov"},{"key":"20324_CR37","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jtumed.2023.08.004","volume":"18","author":"H Yaamika","year":"2023","unstructured":"Yaamika, H., Muralidas, D. & Elumalai, K. Review of adverse events associated with COVID-19 vaccines, highlighting their frequencies and reported cases. J. Taibah Univ. Med. Sci. 18, 1646\u20131661. https:\/\/doi.org\/10.1016\/j.jtumed.2023.08.004 (2023).","journal-title":"J. Taibah Univ. Med. Sci."},{"key":"20324_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal. Transduct. Target. Ther. 7, 94. https:\/\/doi.org\/10.1038\/s41392-022-00950-y (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"20324_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/14.4.411","volume":"14","author":"D Braun","year":"2002","unstructured":"Braun, D., Caramalho, I. & Demengeot, J. IFN-alpha\/beta enhances BCR-dependent B cell responses. Int. Immunol. 14, 411\u2013419. https:\/\/doi.org\/10.1093\/intimm\/14.4.411 (2002).","journal-title":"Int. Immunol."},{"key":"20324_CR40","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1038\/s41467-022-32665-7","volume":"13","author":"Z Zhao","year":"2022","unstructured":"Zhao, Z. et al. Omicron SARS-CoV-2 mutations stabilize Spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape. Nat. Commun. 13, 4958. https:\/\/doi.org\/10.1038\/s41467-022-32665-7 (2022).","journal-title":"Nat. Commun."},{"key":"20324_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3201\/eid2902.221422","volume":"29","author":"DS Khoury","year":"2023","unstructured":"Khoury, D. S. et al. Correlates of protection, thresholds of protection, and Immunobridging among persons with SARS-CoV-2 infection. Emerg. Infect. Dis. 29, 381\u2013388. https:\/\/doi.org\/10.3201\/eid2902.221422 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"20324_CR42","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040. https:\/\/doi.org\/10.1038\/s41591-021-01540-1 (2021).","journal-title":"Nat. Med."},{"key":"20324_CR43","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.063 (2021).","journal-title":"Vaccine"},{"key":"20324_CR44","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: A meta-analysis. Lancet Microbe. 3, e52\u2013e61. https:\/\/doi.org\/10.1016\/S2666-5247(21)00267-6 (2022).","journal-title":"Lancet Microbe"},{"key":"20324_CR45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880. https:\/\/doi.org\/10.1016\/j.cell.2021.01.007 (2021).","journal-title":"Cell"},{"key":"20324_CR46","doi-asserted-by":"publisher","unstructured":"Cecconi, M. et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in lombardy, Italy. J. Clin. Med. 9 https:\/\/doi.org\/10.3390\/jcm9051548 (2020).","DOI":"10.3390\/jcm9051548"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20324-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20324-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20324-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:50:08Z","timestamp":1760712608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20324-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20324"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20324-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. The authors declare that they have no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36395"}}